Notice of Preliminary Results

RNS Number : 2900Z

Epistem Holdings plc

18 September 2009

 

For release: 18 September 2009

Epistem Plc

Notice of Preliminary Results

Epistem Plc (AIM: EHP), the rapidly growing biotechnology company with adult epithelial stem cell expertise in oncology, gastrointestinal and dermatological diseases will announce its Preliminary Results for the year ended 30^th June 2009 on the 6^th October 2009.

The results presentation will be held at the offices of Piper Jaffray at One South Place, London, EC2M 2RB at 9.30am on the day. If you would like to attend, please contact the team at De Facto Communications below. 

For further details please contact:

Epistem

Matthew Walls                         

Chief Executive Officer                      [phone]

John Rylands

Finance Director                     

Piper Jaffray 

Neil Mackison / Rupert Winckler                [phone]

De Facto Communications 

Mike Wort / Anna Dunphy                [phone]

Notes to Editors

Epistem is a biotechnology company commercialising its expertise in epithelial stem cells in the areas of oncology, gastrointestinal and dermatological diseases. Epistem develops innovative therapeutics and biomarkers and provides contract research services to drug development companies. The Group's expertise is focused on the regulation of adult stem cells located in epithelial tissue, which includes the gastrointestinal tract, skin, hair follicles, breast and prostate. Epistem does not conduct research in the areas of embryonic stem cells or stem cell transplantation.

 

END

 

 

NOREAPNPFEKNEEE